Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs.
Avalo is a clinical-stage biotechnology company
fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs.
Developing new medicines targeting the IL-1β pathway
Discover our innovative approach to next-generation treatments for inflammation.
